Zealand Pharma 47th Annual Global Healthcare Conference Key Takeaways

This report summarizes key takeaways from Zealand Pharma's participation in the 47th Annual Global Healthcare Conference, focusing on the clinical progress and commercial positioning of survodutide and petrelintide.

Key Takeaways

• 1.Management was surprised by the vomiting and discontinuations in the SYNCHRONIZE-1 study for survodutide but believes the tolerability profile can be improved through slower, more flexible titration.
• 2.Zealand positions survodutide as having a distinct advantage in targeting hepatic visceral fat reduction, which is clinically important for obese patients.
• 3.Petrelintide remains the primary capital allocation priority, with management focusing on its placebo-like tolerability and long-term efficacy potential.

Table of Contents

• Key Takeaways
• Valuation/Risks
• Disclosure Appendix
• Price target and rating history chart(s)
• Target price history table(s)
• Regulatory disclosures

Document Preview

Page 1 of 1

Subscribe for full accessStart Free Trial